{"type":"trials","record":{"id":42107,"source_id":"clinicaltrials-gov","external_id":"NCT04126317","title":"Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration","brief_summary":"The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred to as IAI).","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Regeneron Pharmaceuticals","enrollment":106,"countries":["United States","Puerto Rico"],"start_date":"2019-11-04","completion_date":"2021-11-30","last_update_date":"2023-08-14","source_url":"https://clinicaltrials.gov/study/NCT04126317","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"CANDELA","age_range":"50 Years","comparator":null,"organization":"Regeneron Pharmaceuticals","interventions":["aflibercept","High-dose aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — Up to Week 44","Number of Participants With at Least One Serious TEAE — Up to Week 44","Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye — At Week 16"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · SINGLE","source_has_results":true},"controlled_terms":["Neovascular (Wet) Age-Related Macular Degeneration","aflibercept","High-dose aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04126317","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-11-04 to 2021-11-30","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.921Z","intervention":["aflibercept","High-dose aflibercept"],"participants":106,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — Up to Week 44","Number of Participants With at Least One Serious TEAE — Up to Week 44","Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye — At Week 16"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42107","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}